ESI-09 is primarily used in research settings as a selective inhibitor of exchange protein directly activated by cAMP (EPAC). It plays a significant role in studying cellular signaling pathways, particularly those involving cAMP and EPAC proteins. Researchers utilize ESI-09 to investigate the mechanisms of EPAC in various physiological processes, such as insulin secretion, cardiovascular function, and cancer progression. By inhibiting EPAC activity, it helps elucidate the protein's role in disease pathways and potential therapeutic targets. Additionally, ESI-09 is employed in pharmacological studies to explore its potential in treating conditions like diabetes, heart disease, and certain cancers, where EPAC signaling is implicated.